ClinicalTrials.gg
CompletedNCT05352815COMBINE 1Updated Dec 4, 2025Results posted

A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Weekly Insulin Icodec

A Phase 3 interventional study of IcoSema and Insulin icodec in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 281 sites in 22 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-04.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,291
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 — 2 open to participants now, 2 under way, none of them phase 3. insulin icodec · Diabetes Mellitus, Type 2.

Enrollment
Largest of 27
1,291 · median 84
Started
2022
with 1 other
Phase 3
9 of 27
none open now
Registered
19th of 27
by date
Lead sponsor
26 of 27
Novo Nordisk A/S

Among the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, this one has the largest enrollment, is one of 2 that started in 2022, is one of 9 in phase 3, and was the 19th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

2 of the 27 studies testing insulin icodec in Diabetes Mellitus, Type 2 are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About insulin icodec

insulin icodec: first FDA approval 2026 (AWIQLI FLEXTOUCH), first EMA approval 2024. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing insulin icodec in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study will compare the new medicine IcoSema, which is a combination of insulin icodec and semaglutide, taken once a week, to insulin icodec taken once a week in people with type 2 diabetes.

The study will look at how well IcoSema controls blood sugar level in people with type 2 diabetes compared to insulin icodec.

Participants will either get IcoSema or insulin icodec. Which treatment participants get is decided by chance. IcoSema and insulin icodec are both new medicines that doctors cannot prescribe.

Participants will get IcoSema or insulin icodec, which participants must inject once a week with a pen, which has a small needle, in a skin fold in the thigh, upper arm, or stomach.

The study will last for about 1 year and 1 month. Participants will have 21 clinic visits, 31 phone/video calls with the study doctor, and 4 contacts with the site that can either be clinic visits or phone/video calls At 11 clinic visits participants will have blood samples taken. At 7 clinic visits participants cannot eat or drink (except for water) for 8 hours before the visit.

Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.

Not applicable for China: Participants will be asked to wear a sensor that measures their blood sugar level all the time during a 5 week period at the end of the study.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key inclusion criteria

  1. Male or female and age above or equal to 18 years at the time of signing .
  2. Diagnosed with type 2 diabetes mellitus 180 days or more before screening.
  3. of 7.0 10.0% (53.0 85.8 mmol/mol) (both inclusive) as assessed by central laboratory on the day of screening.
  4. Treated with once daily or twice daily basal insulin (neutral protamine hagedorn insulin, insulin degludec, insulin detemir, insulin glargine 100 units/mL, or insulin glargine 300 units/mL) 20- 80 units/day for 90 days or more before screening. Short term bolus insulin treatment for a maximum of 14 days before screening is allowed, as is prior insulin treatment for gestational diabetes. The treatment can be with or without any of the following anti diabetic drugs with stable doses for 90 days or more before screening:

    • Metformin
    • Sulfonylureas (a)
    • Meglitinides (glinides) (a)
    • DPP 4 inhibitors (a)
    • Sodium glucose co transporter 2 inhibitors
    • Alpha glucosidase inhibitors
    • Thiazolidinediones
    • Marketed oral combination products only including the products listed above.
  5. (BMI) below or equal to 40.0 kg/m\^2. (a) Sulfonylureas, meglitinides (glinides) and DPP 4 inhibitors must be discontinued at randomisation.

Key exclusion criteria

  1. Female who is pregnant, breast-feeding or intends to become pregnant or is of and not using a highly effective method.
  2. Anticipated initiation or change in concomitant medication (for more than 14 consecutive days) known to affect weight or glucose metabolism (e.g. treatment with orlistat, thyroid hormones, or systemic ).
  3. Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening.
  4. Any episodes (as declared by the participant or in the medical records.) of diabetic ketoacidosis within 90 days before screening.
  5. Presence or history of pancreatitis (acute or chronic) within 180 days before screening.
  6. Any of the following: Myocardial infarction, stroke, hospitalization for unstable angina pectoris or within 180 days before screening.
  7. Chronic heart failure classified as being in Class IV at screening.
  8. Recurrent severe hypoglycaemic episodes within the last year (12 months) as judged by the investigator.
  9. Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within the past 90 days before screening or in the period between screening and randomisation. Pharmacological pupil dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,291 participants (actual)

Study arms

  • Experimental
    IcoSema

    Drug: IcoSema

  • Active comparator
    Insulin icodec

    Drug: Insulin icodec

Interventions

  • DrugIcoSema

    Drug pages: Insulin icodec · Semaglutide

    Participants will receive once weekly IcoSema subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.

  • Participants will receive once weekly Insulin icodec subcutanously (s.c. under the skin) with or without oral anti diabetic drugs for 52 weeks.

06

What researchers measure

Primary outcomes

  1. Change in Glycated Haemoglobin (HbA1c)

    Change from baseline (week 0) to week 52 in HbA1c is presented. The outcome measure was evaluated based on the data from in study period, where all data from randomisation until last date of any of the following: 1) last direct participant-site contact; 2) participants who withdrew their informed consent; 3) last participant-investigator contact as defined by the investigator for participants who lost to follow-up (i.e. possibly an unscheduled phone visit); 4) death of participants who died before any of the above.

    Time frame: Baseline (Week 0), Week 52

Secondary outcomes

  1. Change in Body Weight

    Change from baseline (week 0) to week 52 in body weight is presented. The outcome measure was evaluated based on the data from in study period, where all data from randomisation until last date of any of the following: 1) last direct participant-site contact; 2) participants who withdrew their informed consent; 3) last participant-investigator contact as defined by the investigator for participants who lost to follow-up (i.e. possibly an unscheduled phone visit); 4) death of participants who died before any of the above.

    Time frame: Baseline (Week 0), Week 52

  2. Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Less Than 3.0 Millimoles Per Litre [mmol/L] (54 Milligram Per Decilitre [mg/dL]), Confirmed by Blood Glucose [BG] Meter) or Severe Hypoglycaemic Episodes (Level 3)

    Hypoglycaemic episodes were classified according to the American Diabetes Association/ International Hypoglycaemia Study Group, where glycemic criteria for level 2 was less than (\<) 3.0 mmol/L (54 mg/dL) and level 3 had no specific glucose threshold. The outcome measure was evaluated based on data from on treatment period, where all data from date of first dose of randomised treatment as recorded on the electronic case report form (eCRF) until the first date of any of the following: 1) last follow-up visit ; 2) last date on randomised treatment +6 weeks (corresponding to 5 weeks after the end of the dosing interval for both treatment arms); 3) end-date for the in-study data points sets.

    Time frame: From baseline week 0 to week 57

  3. Percentage of Time in Range 3.9-10.0 mmol/L (70-180 mg/dL) Using Continuous Glucose Monitoring (CGM) System, Dexcom G6

    Time in range was defined as 100 times the number of recorded measurements in glycemic range 3.9-10.0 mmol/L (70-180 mg/dL), both inclusive, divided by the total number of recorded measurements. The outcome measure was evaluated based on the data from in study period: Data from randomisation until last date of any of the following: 1) the last direct participant-site contact; 2) withdrawal for participants who withdraw their informed consent; 3) the last participant-investigator contact as defined by the investigator for participants who are lost to follow-up (i.e. possibly an unscheduled phone visit); 4) death for participants who die before any of the above.

    Time frame: From week 48 to week 52

  4. Percentage of Time Spent < 3.0 mmol/L (54 mg/dL) Using Continuous Glucose Monitoring (CGM) System, Dexcom G6

    Time spent below threshold was defined as 100 times the number of recorded measurements below the threshold, divided by the total number of recorded measurements. The outcome measure was evaluated based on the data from in study period: Data from randomisation until last date of any of the following: 1) the last direct participant-site contact; 2) withdrawal for participants who withdraw their informed consent; 3) the last participant-investigator contact as defined by the investigator for participants who are lost to follow-up (i.e. possibly an unscheduled phone visit); 4) death for participants who die before any of the above.

    Time frame: From week 48 to week 52

  5. Percentage of Time Spent > 10.0 mmol/L (180 mg/dL) Using Continuous Glucose Monitoring (CGM) System, Dexcom G6

    Time spent above threshold is defined as 100 times the number of recorded measurements above the threshold, divided by the total number of recorded measurements. The outcome measure was evaluated based on the data from in study period: Data from randomisation until last date of any of the following: 1) the last direct participant-site contact; 2) withdrawal for participants who withdraw their informed consent; 3) the last participant-investigator contact as defined by the investigator for participants who are lost to follow-up (i.e. possibly an unscheduled phone visit); 4) death for participants who die before any of the above.

    Time frame: From week 48 to week 52

  6. Change in Fasting Plasma Glucose (FPG)

    Change in FPG from baseline (week 0) to week 52 is presented. The outcome measure was evaluated based on the data from in study period: Data from randomisation until last date of any of the following: 1) the last direct participant-site contact; 2) withdrawal for participants who withdraw their informed consent; 3) the last participant-investigator contact as defined by the investigator for participants who are lost to follow-up (i.e. possibly an unscheduled phone visit); 4) death for participants who die before any of the above.

    Time frame: Baseline (Week 0), Week 52

  7. Weekly Basal Insulin Dose

    Estimated mean average weekly basal insulin dose from week 50 to week 52 of treatment is presented. The outcome measure was evaluated based on data from on treatment period, where all data from date of first dose of randomised treatment as recorded on the electronic case report form (eCRF) until the first date of any of the following: 1) last follow-up visit (V56); 2) last date on randomised treatment +6 weeks (corresponding to 5 weeks after the end of the dosing interval for both treatment arms); 3) end-date for the in-study data points sets.

    Time frame: From week 50 to week 52

  8. Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter)

    Hypoglycaemic episodes were classified according to the American Diabetes Association/ International Hypoglycaemia Study Group, where glycemic criteria for level 2 was less than (\<) 3.0 mmol/L (54 mg/dL). The outcome measure was evaluated based on data from on treatment period, where all data from date of first dose of randomised treatment as recorded on the electronic case report form (eCRF) until the first date of any of the following: 1) last follow-up visit ; 2) last date on randomised treatment +6 weeks (corresponding to 5 weeks after the end of the dosing interval for both treatment arms); 3) end-date for the in-study data points sets.

    Time frame: From baseline week 0 to week 57

  9. Number of Severe Hypoglycaemic Episodes (Level 3)

    Hypoglycaemic episodes were classified according to the American Diabetes Association/ International Hypoglycaemia Study Group, where glycemic criteria for level 3 had no specific glucose threshold. The outcome measure was evaluated based on data from on treatment period, where all data from date of first dose of randomised treatment as recorded on the electronic case report form (eCRF) until the first date of any of the following: 1) last follow-up visit; 2) last date on randomised treatment +6 weeks (corresponding to 5 weeks after the end of the dosing interval for both treatment arms); 3) end-date for the in-study data points sets.

    Time frame: From baseline week 0 to week 57

07

Results

Posted Apr 3, 2025

Participant flow

The trial was conducted at 192 sites in 20 countries.

Participant flow — Overall Study
MilestoneIcoSemaInsulin Icodec
Started646645
Treated644644
Full analysis set646645
Safety analysis set644644
Completed611611
Not completed3534
Withdrew: Withdrawal by subject2824
Withdrew: Lost to follow-up47
Withdrew: Death23
Withdrew: Site closure10

Outcome measures

PrimaryChange in Glycated Haemoglobin (HbA1c)

Change from baseline (week 0) to week 52 in HbA1c is presented. The outcome measure was evaluated based on the data from in study period, where all data from randomisation until last date of any of the following: 1) last direct participant-site contact; 2) participants who withdrew their informed consent; 3) last participant-investigator contact as defined by the investigator for participants who lost to follow-up (i.e. possibly an unscheduled phone visit); 4) death of participants who died before any of the above.

Time frame:
Baseline (Week 0), Week 52
Reported as:
Mean · Percentage point of HbA1c
Change in Glycated Haemoglobin (HbA1c)
Percentage point of HbA1cIcoSemaInsulin Icodec
Change in Glycated Haemoglobin (HbA1c)-1.60 ± 0.99-0.90 ± 1.01
Statistical analysis
  • IcoSema vs Insulin Icodec · ANCOVA · p = <0.0001 · Treatment difference: -0.66 · 95% CI -0.76 to -0.57
SecondaryChange in Body Weight

Change from baseline (week 0) to week 52 in body weight is presented. The outcome measure was evaluated based on the data from in study period, where all data from randomisation until last date of any of the following: 1) last direct participant-site contact; 2) participants who withdrew their informed consent; 3) last participant-investigator contact as defined by the investigator for participants who lost to follow-up (i.e. possibly an unscheduled phone visit); 4) death of participants who died before any of the above.

Time frame:
Baseline (Week 0), Week 52
Reported as:
Mean · Kilogram (Kg)
Change in Body Weight
Kilogram (Kg)IcoSemaInsulin Icodec
Change in Body Weight-3.71 ± 4.871.96 ± 4.76
SecondaryNumber of Clinically Significant Hypoglycaemic Episodes (Level 2) (Less Than 3.0 Millimoles Per Litre [mmol/L] (54 Milligram Per Decilitre [mg/dL]), Confirmed by Blood Glucose [BG] Meter) or Severe Hypoglycaemic Episodes (Level 3)

Hypoglycaemic episodes were classified according to the American Diabetes Association/ International Hypoglycaemia Study Group, where glycemic criteria for level 2 was less than (\<) 3.0 mmol/L (54 mg/dL) and level 3 had no specific glucose threshold. The outcome measure was evaluated based on data from on treatment period, where all data from date of first dose of randomised treatment as recorded on the electronic case report form (eCRF) until the first date of any of the following: 1) last follow-up visit ; 2) last date on randomised treatment +6 weeks (corresponding to 5 weeks after the end of the dosing interval for both treatment arms); 3) end-date for the in-study data points sets.

Time frame:
From baseline week 0 to week 57
Reported as:
Number · Episodes
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Less Than 3.0 Millimoles Per Litre [mmol/L] (54 Milligram Per Decilitre [mg/dL]), Confirmed by Blood Glucose [BG] Meter) or Severe Hypoglycaemic Episodes (Level 3)
EpisodesIcoSemaInsulin Icodec
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (Less Than 3.0 Millimoles Per Litre [mmol/L] (54 Milligram Per Decilitre [mg/dL]), Confirmed by Blood Glucose [BG] Meter) or Severe Hypoglycaemic Episodes (Level 3)91424
SecondaryPercentage of Time in Range 3.9-10.0 mmol/L (70-180 mg/dL) Using Continuous Glucose Monitoring (CGM) System, Dexcom G6

Time in range was defined as 100 times the number of recorded measurements in glycemic range 3.9-10.0 mmol/L (70-180 mg/dL), both inclusive, divided by the total number of recorded measurements. The outcome measure was evaluated based on the data from in study period: Data from randomisation until last date of any of the following: 1) the last direct participant-site contact; 2) withdrawal for participants who withdraw their informed consent; 3) the last participant-investigator contact as defined by the investigator for participants who are lost to follow-up (i.e. possibly an unscheduled phone visit); 4) death for participants who die before any of the above.

Time frame:
From week 48 to week 52
Reported as:
Mean · Percentage of time
Percentage of Time in Range 3.9-10.0 mmol/L (70-180 mg/dL) Using Continuous Glucose Monitoring (CGM) System, Dexcom G6
Percentage of timeIcoSemaInsulin Icodec
Percentage of Time in Range 3.9-10.0 mmol/L (70-180 mg/dL) Using Continuous Glucose Monitoring (CGM) System, Dexcom G675.9 ± 16.161.9 ± 18.1
SecondaryPercentage of Time Spent < 3.0 mmol/L (54 mg/dL) Using Continuous Glucose Monitoring (CGM) System, Dexcom G6

Time spent below threshold was defined as 100 times the number of recorded measurements below the threshold, divided by the total number of recorded measurements. The outcome measure was evaluated based on the data from in study period: Data from randomisation until last date of any of the following: 1) the last direct participant-site contact; 2) withdrawal for participants who withdraw their informed consent; 3) the last participant-investigator contact as defined by the investigator for participants who are lost to follow-up (i.e. possibly an unscheduled phone visit); 4) death for participants who die before any of the above.

Time frame:
From week 48 to week 52
Reported as:
Mean · Percentage of time
Percentage of Time Spent < 3.0 mmol/L (54 mg/dL) Using Continuous Glucose Monitoring (CGM) System, Dexcom G6
Percentage of timeIcoSemaInsulin Icodec
Percentage of Time Spent < 3.0 mmol/L (54 mg/dL) Using Continuous Glucose Monitoring (CGM) System, Dexcom G60.27 ± 0.550.33 ± 0.82
SecondaryPercentage of Time Spent > 10.0 mmol/L (180 mg/dL) Using Continuous Glucose Monitoring (CGM) System, Dexcom G6

Time spent above threshold is defined as 100 times the number of recorded measurements above the threshold, divided by the total number of recorded measurements. The outcome measure was evaluated based on the data from in study period: Data from randomisation until last date of any of the following: 1) the last direct participant-site contact; 2) withdrawal for participants who withdraw their informed consent; 3) the last participant-investigator contact as defined by the investigator for participants who are lost to follow-up (i.e. possibly an unscheduled phone visit); 4) death for participants who die before any of the above.

Time frame:
From week 48 to week 52
Reported as:
Mean · Percentage of time
Percentage of Time Spent > 10.0 mmol/L (180 mg/dL) Using Continuous Glucose Monitoring (CGM) System, Dexcom G6
Percentage of timeIcoSemaInsulin Icodec
Percentage of Time Spent > 10.0 mmol/L (180 mg/dL) Using Continuous Glucose Monitoring (CGM) System, Dexcom G623.2 ± 16.336.7 ± 18.7
SecondaryChange in Fasting Plasma Glucose (FPG)

Change in FPG from baseline (week 0) to week 52 is presented. The outcome measure was evaluated based on the data from in study period: Data from randomisation until last date of any of the following: 1) the last direct participant-site contact; 2) withdrawal for participants who withdraw their informed consent; 3) the last participant-investigator contact as defined by the investigator for participants who are lost to follow-up (i.e. possibly an unscheduled phone visit); 4) death for participants who die before any of the above.

Time frame:
Baseline (Week 0), Week 52
Reported as:
Mean · Millimoles per litre (mmol/L)
Change in Fasting Plasma Glucose (FPG)
Millimoles per litre (mmol/L)IcoSemaInsulin Icodec
Change in Fasting Plasma Glucose (FPG)-1.90 ± 3.01-1.65 ± 2.96
SecondaryWeekly Basal Insulin Dose

Estimated mean average weekly basal insulin dose from week 50 to week 52 of treatment is presented. The outcome measure was evaluated based on data from on treatment period, where all data from date of first dose of randomised treatment as recorded on the electronic case report form (eCRF) until the first date of any of the following: 1) last follow-up visit (V56); 2) last date on randomised treatment +6 weeks (corresponding to 5 weeks after the end of the dosing interval for both treatment arms); 3) end-date for the in-study data points sets.

Time frame:
From week 50 to week 52
Reported as:
Mean · Units of insulin
Weekly Basal Insulin Dose
Units of insulinIcoSemaInsulin Icodec
Weekly Basal Insulin Dose170.6 ± 83.3366.5 ± 225.5
SecondaryNumber of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter)

Hypoglycaemic episodes were classified according to the American Diabetes Association/ International Hypoglycaemia Study Group, where glycemic criteria for level 2 was less than (\<) 3.0 mmol/L (54 mg/dL). The outcome measure was evaluated based on data from on treatment period, where all data from date of first dose of randomised treatment as recorded on the electronic case report form (eCRF) until the first date of any of the following: 1) last follow-up visit ; 2) last date on randomised treatment +6 weeks (corresponding to 5 weeks after the end of the dosing interval for both treatment arms); 3) end-date for the in-study data points sets.

Time frame:
From baseline week 0 to week 57
Reported as:
Number · Episodes
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter)
EpisodesIcoSemaInsulin Icodec
Number of Clinically Significant Hypoglycaemic Episodes (Level 2) (<3.0 mmol/L (54 mg/dL), Confirmed by BG Meter)90419
SecondaryNumber of Severe Hypoglycaemic Episodes (Level 3)

Hypoglycaemic episodes were classified according to the American Diabetes Association/ International Hypoglycaemia Study Group, where glycemic criteria for level 3 had no specific glucose threshold. The outcome measure was evaluated based on data from on treatment period, where all data from date of first dose of randomised treatment as recorded on the electronic case report form (eCRF) until the first date of any of the following: 1) last follow-up visit; 2) last date on randomised treatment +6 weeks (corresponding to 5 weeks after the end of the dosing interval for both treatment arms); 3) end-date for the in-study data points sets.

Time frame:
From baseline week 0 to week 57
Reported as:
Number · Episodes
Number of Severe Hypoglycaemic Episodes (Level 3)
EpisodesIcoSemaInsulin Icodec
Number of Severe Hypoglycaemic Episodes (Level 3)15

Adverse events

Collected over Week 0 to week 57. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Icodec3/645 (0.5%)69/644 (10.7%)258/644 (40.1%)
IcoSema2/646 (0.3%)59/644 (9.2%)354/644 (55%)
Most frequent serious events
Showing 10 of 139
Most frequent serious events
EventIcodecIcoSema
Acute myocardial infarctionCardiac disorders5/6442/644
Coronary artery diseaseCardiac disorders4/6440/644
PneumoniaInfections and infestations4/6440/644
Coronary artery stenosisCardiac disorders3/6440/644
DyspnoeaRespiratory, thoracic and mediastinal disorders3/6440/644
GastroenteritisInfections and infestations1/6443/644
HypoglycaemiaMetabolism and nutrition disorders3/6440/644
Abdominal painGastrointestinal disorders2/6440/644
Acute respiratory failureRespiratory, thoracic and mediastinal disorders2/6440/644
ArthralgiaMusculoskeletal and connective tissue disorders0/6442/644
Most frequent other events
Showing 10 of 12
Most frequent other events
EventIcodecIcoSema
NauseaGastrointestinal disorders24/644153/644
DiarrhoeaGastrointestinal disorders46/644102/644
Upper respiratory tract infectionInfections and infestations69/64454/644
VomitingGastrointestinal disorders17/64468/644
COVID-19Infections and infestations61/64467/644
NasopharyngitisInfections and infestations51/64438/644
DyspepsiaGastrointestinal disorders10/64444/644
Diabetic retinopathyEye disorders35/64441/644
ConstipationGastrointestinal disorders8/64439/644
Decreased appetiteMetabolism and nutrition disorders1/64438/644

Baseline characteristics

Full analysis set (FAS) included all randomised participants.

Age, Continuous
Age, Continuous(Years)IcoSemaInsulin IcodecTotal
Mean60.5 ± 10.560.7 ± 10.260.6 ± 10.3
Sex: Female, Male
Sex: Female, Male(Participants)IcoSemaInsulin IcodecTotal
Female246246492
Male400399799
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)IcoSemaInsulin IcodecTotal
Hispanic or Latino101110211
Not Hispanic or Latino5455351080
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)IcoSemaInsulin IcodecTotal
American Indian or Alaska Native516
Asian216204420
Native Hawaiian or Other Pacific Islander011
Black or African American192544
White404410814
More than one race246
Unknown or Not Reported000
08

Study locations

281 sites
  • Pri Med Grp dba/Gil Ctr Fam
    Gilbert, Arizona 85296, United States
  • Lenzmeier Fam Med CCT Research
    Glendale, Arizona 85308, United States
  • Phoenician Centers for Research & Innovation PCRI
    Phoenix, Arizona 85021, United States
  • Medical Investigations, Inc.
    Little Rock, Arkansas 72211, United States
  • John Muir Physicians Network
    Concord, California 94520, United States
  • Headlands Research California, LLC
    Escondido, California 92025, United States
  • Scripps Whittier Diabetes Inst
    La Jolla, California 92037, United States
  • Clinical Trials Research_Sacramento
    Lincoln, California 95648, United States
  • Torrance Clin Res Inst, Inc.
    Lomita, California 90717, United States
  • Pacific Clinical Studies
    Los Alamitos, California 90720, United States
  • Downtown LA Res Ctr. Inc.
    Los Angeles, California 90017, United States
  • Velocity Clin Res Los Angeles
    Los Angeles, California 90017, United States
  • Valley Clinical Trials, Inc.
    Northridge, California 91325, United States
  • Clinical Trials Research_Sacramento_0
    Sacramento, California 95821, United States
  • San Diego Family Care
    San Diego, California 92111, United States
  • NorCal Endocrinology and Internal Medicine
    San Ramon, California 94583, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Creekside Endocrine Associates, PC
    Denver, Colorado 80246, United States
  • Clinical Res Of W Florida Inc
    Clearwater, Florida 33765, United States
  • Northeast Research Institute
    Fleming Island, Florida 32003, United States
  • University of Miami
    Miami, Florida 33136, United States
  • Adult Medicine of Lake County, Inc.
    Mt. Dora, Florida 32757, United States
  • Suncoast Clin Res Port Richey
    New Port Richey, Florida 34652, United States
  • Clinical Neuroscience Solution
    Orlando, Florida 32801, United States
  • Florida Inst For Clin Res
    Orlando, Florida 32825, United States
  • Metabolic Research Institute Inc
    West Palm Beach, Florida 33401, United States
  • Javara/Privia Med Grp GA,LLC
    Albany, Georgia 31707, United States
  • Emory University SOM
    Atlanta, Georgia 30303, United States
  • Javara Inc.
    Fayetteville, Georgia 30214, United States
  • Physicians Research Assoc. LLC
    Lawrenceville, Georgia 30046, United States
  • Endocrine Research Solutions
    Roswell, Georgia 30076, United States
  • East West Med Res Inst
    Honolulu, Hawaii 96814, United States
  • Saltzer Medical Group Research
    Nampa, Idaho 83686-6011, United States
  • UnityPoint Health-Diabetes Care Center
    Peoria, Illinois 61603, United States
  • Endeavor Health
    Skokie, Illinois 60077, United States
  • Iowa Diab & Endo Res Center
    West Des Moines, Iowa 50266, United States
  • Cotton O'Neil Diab & Endo Ctr
    Topeka, Kansas 66606, United States
  • The Research Group of Lexington LLC
    Lexington, Kentucky 40503, United States
  • Barnum Medical Research Inc.
    Natchitoches, Louisiana 71457, United States
  • New Orleans Center for Clinical Research
    New Orleans, Louisiana 70119, United States
  • Ileana J Tandron APMC
    Slidell, Louisiana 70461-4231, United States
  • MedStar Hlth Res Institute
    Hyattsville, Maryland 20782, United States
  • Brigham & Women's Hospital
    Boston, Massachusetts 02115-5804, United States
  • MassResearch, LLC
    Waltham, Massachusetts 02453, United States
  • Northern Pines Hlth Ctr, PC
    Buckley, Michigan 49620, United States
  • Elite Research Center
    Flint, Michigan 48532, United States
  • International Diabetes Center
    Minneapolis, Minnesota 55416, United States
  • StudyMetrix Research LLC
    City of Saint Peters, Missouri 63303, United States
  • Jefferson City Medical Group, PC
    Jefferson City, Missouri 65109, United States
  • Methodist Phys. Clinic
    Omaha, Nebraska 68114, United States
  • University of NE Med Ctr
    Omaha, Nebraska 68198, United States
  • University of Nevada School of Medicine
    Las Vegas, Nevada 89102, United States
  • Palm Research Center Inc.
    Las Vegas, Nevada 89148, United States
  • Southern New Hampshire Diabete
    Nashua, New Hampshire 03060, United States
  • John J Shelmet, MD
    Lawrenceville, New Jersey 08648, United States
  • Albuquerque Clin Trials, Inc.
    Albuquerque, New Mexico 87102, United States
  • Mid Hudson Medical Research, PLLC
    New Windsor, New York 12553, United States
  • DiGiovanna Institute for Medical Education & Research
    North Massapequa, New York 11758-1802, United States
  • Endocrine Associates of Long Island, PC
    Smithtown, New York 11787, United States
  • SUNY Upstate Medical University
    Syracuse, New York 13210, United States
  • Southgate Medical Group, LLP
    West Seneca, New York 14224, United States
  • Javara Inc. / Tryon Medical Partners PLLC
    Charlotte, North Carolina 28287, United States
  • PharmQuest Life Sciences LLC
    Greensboro, North Carolina 27408, United States
  • Central Ohio Clinical Research LLC
    Columbus, Ohio 43213, United States
  • Prestige Clinical Research
    Franklin, Ohio 45005, United States
  • New Venture Medical Research
    Wadsworth, Ohio 44281, United States
  • Intend Research
    Norman, Oklahoma 73069, United States
  • Care Access
    Warwick, Rhode Island 02886, United States
  • Palmetto Clinical Research
    Summerville, South Carolina 29485, United States
  • Athens Medical Group
    Athens, Tennessee 37303, United States
  • AM Diabetes And Endocrinology Center
    Bartlett, Tennessee 38133, United States
  • Holston Medical Group_Bristol
    Bristol, Tennessee 37620, United States
  • Chattanooga Medical Research, LLC
    Chattanooga, Tennessee 37404, United States
  • Univ Diab & Endo Consultants
    Chattanooga, Tennessee 37411, United States
  • HealthStar Physicians PC
    Morristown, Tennessee 37813, United States
  • Amarillo Med Spec LLP
    Amarillo, Texas 79106, United States
  • Texas Diabetes & Endocrinology, P.A._Austin
    Austin, Texas 78731, United States
  • Texas Diabetes & Endocrinology, P.A._Austin
    Austin, Texas 78749, United States
  • Osvaldo A. Brusco MD PA
    Corpus Christi, Texas 78414, United States
  • Cedar Research
    Dallas, Texas 75038, United States
  • Velocity Clinical Res-Dallas
    Dallas, Texas 75230, United States
  • North Texas Endocrine Center
    Dallas, Texas 75231, United States
  • Univ of TX SW Med Ctr Dallas
    Dallas, Texas 75390-9302, United States
  • Diabetes and Thyroid Ctr of FW
    Fort Worth, Texas 76132, United States
  • PrimeCare Medical Group
    Houston, Texas 77024, United States
  • Javara Inc. / Privia Medical Group Gulf Coast PLLC
    Houston, Texas 77054, United States
  • PlanIt Research, PLLC
    Houston, Texas 77079, United States
  • Protenium Clinical Research
    Hurst, Texas 76054, United States
  • Medical Colleagues-Texas LLP
    Katy, Texas 77450, United States
  • Andres Garcia-Zuniga, MD, P.A
    Laredo, Texas 78041, United States
  • Milton Haber, M.D.
    Laredo, Texas 78041, United States
  • DCOL Ctr for Clin Res
    Longview, Texas 75605, United States
  • Clinical Investigations Of Texas
    Plano, Texas 75075, United States
  • Texas Diabetes &Endocrinology
    Round Rock, Texas 78681, United States
  • Sun Research Institute
    San Antonio, Texas 78215, United States
  • Briggs Clinical Research, LLC
    San Antonio, Texas 78224, United States
  • Audie L. Murphy VA Hospital
    San Antonio, Texas 78229, United States
  • Diabetes & Gladular Disease Research A Cetero Research Co
    San Antonio, Texas 78229, United States
  • Diabetes Glandular Diseases Clinic
    San Antonio, Texas 78229, United States
  • Javara Inc Privia Grp Gulf Cst
    San Marcos, Texas 78666, United States

Showing the first 100 of 281 sites across 22 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • De Block C, Benamar M, Fu A, Maltesen R, Giorgino F. CGM-derived postprandial glucose with IcoSema versus other insulin regimens: a post hoc analysis of COMBINE 1 and 3. EClinicalMedicine. 2026 Jun 4;96:103985. doi: 10.1016/j.eclinm.2026.103985. eCollection 2026 Jun. PubMed 42306490 ↗
  • Mathieu C, Giorgino F, Kim SG, Larsen JH, Philis-Tsimikas A, Ramachandran A, Pagliaro Rocha TM, Shankarappa VB, Terauchi Y, Ji L. Once-weekly IcoSema versus once-weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open-label, multicentre, treat-to-target, randomised, phase 3a trial. Lancet Diabetes Endocrinol. 2025 Jul;13(7):568-579. doi: 10.1016/S2213-8587(25)00096-8. Epub 2025 Jun 4. PubMed 40482671 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Mar 2024, 21 months.

Results were first posted in Apr 2025, 1 year after primary completion.

Of 438 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 26. This study's 21 months is above that.

Counting every sponsor, half of 525 studies reached it within 20 months; a quarter within 14 and three quarters within 30.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2022
First posted
Apr 29, 2022
StartActual
Jun 1, 2022
Primary completionActual
Mar 19, 2024
CompletionActual
Apr 23, 2024
Results first posted
Apr 3, 2025
Last update
Dec 4, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 4, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05352815
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Apr 29, 2022
Start date
Jun 1, 2022
Primary completion
Mar 19, 2024
Completion
Apr 23, 2024
Results posted
Apr 3, 2025
Last update
Dec 4, 2025

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Insulin icodec · Semaglutide

Start the discussion